Iga Swiatek accepts one-month suspension after failing doping test, says ITIA
Sign up now: Get the biggest sports news in your inbox
Poland's Iga Swiatek tested positive in an out-of-competition sample in August, but the ITIA accepted that it was caused by contamination of her medication for jet lag and sleep issues.
PHOTO: USA TODAY SPORTS
LONDON – World No. 2 and five-time Grand Slam champion Iga Swiatek has accepted a one-month suspension after testing positive for banned substance trimetazidine, the International Tennis Integrity Agency (ITIA) said on Nov 28.
She tested positive in an out-of-competition sample in August but the ITIA accepted that it was caused by contamination of her melatonin medication, which was manufactured and sold in Poland.
Swiatek, 23, had been taking it for jet lag and sleep issues and, as there was no significant fault or negligence, the ITIA offered the French Open champion a one-month suspension, which she accepted.
“The player was provisionally suspended from Sept 22 until Oct 4, missing three tournaments, which counts towards the sanction, leaving eight days remaining,” the ITIA said in a statement.
“In addition, the player also forfeits prize money from the Cincinnati Open, the tournament directly following the test.”
Swiatek, who had pulled out of tournaments in Asia in September citing personal matters and fatigue, described the ordeal of testing positive as the “worst experience of my life”.
She was world No. 1 when she failed the test and, having skipped the Asian swing, Aryna Sabalenka leapfrogged her in the rankings to eventually end the year as No. 1.
“In the last 2.5 months I was subject to strict ITIA proceedings, which confirmed my innocence,” Swiatek said on Instagram.
“The only positive doping test in my career, showing unbelievably low level of a banned substance I’ve never heard about before, put everything I’ve worked so hard for my entire life into question.
“Both me and my team had to deal with tremendous stress and anxiety.”
Swiatek is not the first world No. 1 to fail a doping test in 2024 after Italy’s Jannik Sinner, the men’s top-ranked player, also tested positive for anabolic agent clostebol.
However, he was cleared of wrongdoing by an independent tribunal ahead of the US Open, which he went on to win.
Swiatek played in Cincinnati, where she was the top seed and reached the semi-finals. The WTA said she won nearly US$159,000 (S$214,000) in prize money at the tournament won by Sabalenka.
She then took part in the US Open, where she was knocked out in the quarter-finals, before the WTA Finals in Riyadh where she failed to advance from the group stage.
She also represented Poland at the Billie Jean King Cup, where they lost in the semi-finals to eventual champions Italy.
Swiatek said on Instagram that the ITIA proceedings had confirmed her innocence.
SCREENSHOTS: INSTAGRAM/IGA SWIATEK
The women’s tour (WTA) said they acknowledged the ITIA’s decision and that they “fully support” Swiatek.
“This unfortunate incident highlights the challenges athletes face in navigating the use of medications and supplements,” the WTA added.
Russian figure skater Kamila Valieva also tested positive for trimetazidine, with the result revealed during the 2022 Winter Olympics.
She was disqualified from the team competition at the Beijing Games and was handed a four-year ban. REUTERS
